REGULATORY

• Panelists Wary of Proposed Switch of Generic GMP Inspection Authority to PMDA
  July 8, 2024

• Minister Nudges Generic Product Consolidation, Pitches “5 Makers per API”
  July 5, 2024

• LDP Veteran Seiichi Eto to Bow Out from Politics Next Summer
  July 5, 2024

• Payer Chides AnGes’s Course Change on Collategene, Urges Re-Think of System’s Set-Up
  July 4, 2024

• Over 60% of Generic Firms Carry Jointly Developed Products, 98% of Espha Drugs Fall into This Category
  July 3, 2024

• LDP Group Calls for MCI Screening for Early Detection of Alzheimer’s
  July 3, 2024

• New ICH Topic on RWD to Be Proposed towards Its Use in Regulatory Review
  July 2, 2024

• Sato Named MHLW’s Top Pharmacy Officer; Kiyohara to Steer Drug Pricing Reform
  July 2, 2024

• MHLW Shuffles Senior Bureaucrats, Ihara Tapped as Vice Health Minister
  July 2, 2024

• PMDA Kicks Off Consultations for Pediatric and Rare Disease Drugs
  July 2, 2024

• PMDA Opens 1st Overseas Office in Bangkok
  July 2, 2024

• Minister Wants Consensus on Future Generic Industry at Upcoming Confab
  July 1, 2024

• MHLW to Revise Process to Share Info on Nitrosamine Impurities after Guidance Issued
  June 28, 2024

• MHLW Project Team Proposes New Subsidies for Early R&D of Intractable Disease Drugs
  June 28, 2024

• MHLW Sets Up Global Strategy HQ to Bolster Innovation Ecosystem
  June 28, 2024

• MHLW Panel OKs Different Safety Scheme for Fujimoto’s Revlimid Generic despite Concerns
  June 27, 2024

• Constitutional Democratic Party Calls for Scrapping Off-Year Price Revisions
  June 27, 2024

• Sakigake Tag to Be Withdrawn for Lisata’s Cell Therapy CLBS12
  June 27, 2024

• Health Minister Set to Meet Generic Execs to Hear Views on Industry Revamp
  June 26, 2024

• Japan's First Eylea Biosimilar Wins Nod, Potential Listing in November
  June 25, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 45
• 46
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• …
• Next ›
• 最終 »